|
Keros Therapeutics Inc (NASDAQ: KROS) |
|
Keros Therapeutics Inc
KROS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Keros Therapeutics Inc growth rates, revenue grew
by 3602.46 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 16
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
Keros Therapeutics Inc realized net income compared to net loss a year ago in first quarter of 2025
• More on KROS's Growth
|
|
Keros Therapeutics Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Keros Therapeutics Inc PEG ratio is at -19.45
Company is currently trading with Price to Cash flow multiple of 2 in trailing twelve-month period. |
Company |
1947.55 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
• More on KROS's Valuation
|
|
|
|
|
Keros Therapeutics Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Keros Therapeutics Inc PEG ratio is at -19.45
Company is currently trading with Price to Cash flow multiple of 2 in trailing twelve-month period. |
Company |
1947.55 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
Keros Therapeutics Inc Price to Book Ratio is at 0.76 lower than Industry Avg. of 33.92. and higher than S&P 500 Avg. of 0.01
• More on KROS's Valuation
|
|
KROS's Profitability Comparisons
|
Keros Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 69.73 %.
Keros Therapeutics Inc net profit margin of 68.08 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 16 in Healthcare sector and number 86 in S&P 500.
Profitability by Segment |
Total |
68.08 % |
|
|
Keros Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 69.73 %.
Keros Therapeutics Inc net profit margin of 68.08 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 16 in Healthcare sector and number 86 in S&P 500.
• More on KROS's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com